The value of new drugs
| Reference number | |
| Coordinator | STUDIEFÖRBUNDET NÄRINGSLIV O SAMHÄLLE - Studieförbundet Näringsliv och Samhälle |
| Funding from Vinnova | SEK 600 000 |
| Project duration | June 2011 - December 2013 |
| Status | Completed |
Purpose and goal
The purpose of this research program was to improve the knowledge basis for decisions governing the introduction and use of phamaceuticals in Sweden. The value of primarily new drugs should be studied with a broad and long-range societal perspective. This was done successfully by both theoretical and empirical studies. The aim was to support methods development, to demonstrate how knowledge of their value can contribute to better introduction and use of pharmaceuticals, and to support policy formation in the field. These ambitions were realized.
Results and expected effects
The research reports showing how the value of pharmaceuticals can be studied and measured were received positively by decisionmakers and researchers in the field. They were covered by relevant media. A reference group supporting the research program submitted a written statement endorsing its relevance and value. Participants in conferences and seminars expressed their appreciation. To what extent the research programs and its findings have had an impact on decisions in the pharmaceutical area has not been studied.
Approach and implementation
The research started in 2011 with a pilot study followed by 12 mainly empirical studies. More than 30 university researchers contributed. Their studies were reported successively. Research findings and policy conclusions were presented and discussed. The final report, ´Värdet av läkemedel´ (The value of pharmaceuticals), was discussed at a conference on 22 November 2013. Representatives of politics, government agencies, county councils, health care providers, the pharma industry and patients participated. Both the design and the execution of the program worked well.